Evidence map›Paper›PMID 34163168›Full record

ReviewVascular health and risk management2021

Ticagrelor Use in Stroke Patients: Past, Present, and Future.

Rahul Chandra, Harneel Saini, Russell Cerejo, Ashis Tayal, Konark Malhotra

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vascular health and risk management, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Lung protective effect of Ticagrelor in endotoxemia.Journal of medicine and life · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Rahul ChandraDepartment of Neurology, Allegheny Health Network, Pittsburgh, PA, USA.
Harneel SainiDepartment of Neurology, Allegheny Health Network, Pittsburgh, PA, USA.
Russell CerejoDepartment of Neurology, Allegheny Health Network, Pittsburgh, PA, USA.
Ashis TayalDepartment of Neurology, Allegheny Health Network, Pittsburgh, PA, USA.
Konark MalhotraDepartment of Neurology, Allegheny Health Network, Pittsburgh, PA, USA.
Allegheny Health Network · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antiplatelet medications are the mainstay for secondary stroke treatment. Aspirin, clopidogrel, and aspirin-dipyridamole are commonly used antiplatelet medications. Other antiplatelet medications such as ticagrelor and prasugrel have been majorly used in cardiovascular or neuro-interventional specialties. Recent studies have paved a way to their use in secondary stroke prevention. In this review, we have briefly discussed the pharmacology of ticagrelor, published literature in cardiology and stroke trials, use of ticagrelor among patients with ischemic strokes, and compared its efficacy, limitations and side-effects with other antiplatelet medications.

Indexed as

Secondary PreventionHemorrhageHumansIschemic StrokePlatelet Aggregation InhibitorsRisk AssessmentRisk FactorsTicagrelorTreatment OutcomePlatelet Aggregation InhibitorsTicagrelorclopidogrelplatelet inhibitionstrokeTicagrelor

Identifiers

PMID34163168
PMCPMC8214569
OpenAlexW3172272531

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.